Q4 2024 / Q4 2024 Q4 2024. Display Title. Q4 2024. Weight. 0. Sub-group. Q4. Group. 2024. Content. Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results. Regeneron Pharmaceuticals Q4 2024 Earnings Conference Call. ... You are now leaving Investor.Regeneron.com. The site you are about to visit is maintained by a ...

3 days ago · Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase ... except per share data) Q4 2024 Q4 2023 % Change FY 2024 FY 2023 % Change Total revenues $ 3,789 $ 3,434 10 % $ 14,202 $ 13,117 8 % GAAP net income $ 918 $ 1,160 (21 %) $ 4,413 $ 3,954 12 % ...

3 days ago · Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to ~$4.5 Billion ... Q4 2024 . Q4 ...

2 days ago · Revenue Growth: 10% year-over-year increase to $3.8 billion in Q4 2024. Net Income: $1.4 billion in Q4 2024, with diluted net income per share of $12.07. Full Year Revenue: $14.2 billion for 2024 ...

2 days ago · Regeneron reported Q4 2024 earnings today - revenues were up 10% YoY to $3.79bn. Full-year revenues were up 8% to $14.2bn. Q4 GAAP EPS at $8.06, and $38 adj. full-year. The company declared its ...

Regeneron Pharmaceuticals Q4 2023 Earnings Conference Call. Regeneron February 2024 Corporate Presentation 2.2 MB. Q4 2023 Earnings Conference Call Transcript 431.1 KB. Form 10-K. Q3 Regeneron Reports Third Quarter 2023 Financial and Operating Results. ... You are now leaving Investor.Regeneron.com. The site you are about to visit is maintained ...

3 days ago · Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 per ...

2 days ago · Regeneron posted Q4 adjusted EPS of $12.07, beating the $11.29 consensus. Sales rose 10% to $3.79B, surpassing the $3.75B estimates. Eylea HD and Eylea U.S. sales grew 2% Y/Y to $1.49B, while ...

3 days ago · Global net sales of the immunology drug jumped 15% to $3.70 billion in Q4. "Regeneron's financial and commercial strength allows for continued investment in our industry-leading R&D pipeline, while simultaneously returning capital to our shareholders through our newly initiated dividend program and increased share repurchase capacity," said ...

Nov 19, 2024 · Listen to the Regeneron Pharmaceuticals Q4 2024 Earnings Conference Call webcast